Unleashing the power of anti-HER2 therapies in metastatic colorectal cancer: paving the way for a brighter future.

ABSTRACT: Colorectal cancer (CRC) constitutes a significant portion of cancer-related deaths in the United States, topping cancer-related mortality among males under 50 years of age. Despite an increase in overall survival throughout the years, the prognosis of metastatic CRC remains poor. In addition to the classic molecular targets in CRC that include epidermal growth factor receptor, BRAF, and vascular endothelial growth factor pathways, human epidermal growth factor receptor 2 (HER2) amplification is an emerging target that has been successfully targeted in advanced CRC, particularly with anti-HER2 monoclonal antibodies and tyrosine kinase inhibitors. With the introduction of potent HER2-directed antibody-drug conjugates, the number of patients who might be eligible for anti-HER2 therapy is expe

SUBMITTER: Babkoff A 

PROVIDER: S-EPMC12836600 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature